From Botanical Starting Material to a Phase-Appropriate Pharmaceutical Control Strategy

Advancing a botanical-derived product into clinical development presents a distinctive quality and CMC challenge. Unlike a conventional synthetic drug substance, a botanical-derived product may originate from naturally variable material whose characteristics are influenced by the upstream supply chain. When that material is sourced externally and subsequently incorporated into a pharmaceutical manufacturing process, the development program must establish appropriate controls across the transition from starting material to drug substance and, ultimately, finished drug product.

This case involved an international clinical-stage pharmaceutical and biotechnology sponsor based in Victoria, Australia, developing a botanical-derived pharmaceutical product for Phase 2 clinical development. The program operated through an outsourced manufacturing and testing network encompassing the starting-material supplier, drug substance and drug product manufacturers, specialist analytical laboratories and other external service providers.

The initial engagement focused on establishing a phase-appropriate Pharmaceutical Quality System (PQS) and Document Management System (DMS). As the program progressed toward Phase 2, however, the quality requirements expanded substantially. Manufacturing controls, analytical methods, specifications, stability studies, supplier oversight and regulatory documentation needed to develop in parallel with increasing knowledge of the product and process.

The resulting program required an integrated approach to Quality, CMC and regulatory activities while maintaining controls proportionate to the development stage.

Establishing the Quality Foundation for Clinical Development

The starting point was the establishment of a PQS and supporting DMS suitable for a lean clinical-stage organisation. The objective was not to replicate a commercial pharmaceutical quality organisation prematurely, but to establish the governance, documentation and decision-making mechanisms required to support GMP activities and clinical manufacturing.

The system incorporated procedures, forms, registers and operational tools covering document control, data integrity and good documentation practices, training, vendor management, quality risk management, change control, deviations, CAPA, audits, Quality Agreements, validation and batch management.

A central consideration was scalability. The quality system needed to support immediate clinical-development requirements while remaining capable of evolving as the program generated additional product and process knowledge. This avoided designing a system that would require wholesale replacement whenever the development program entered a subsequent phase.

The DMS also provided an organisational structure for controlled documentation and records, supporting traceability across activities performed by the Sponsor and its external partners.

Translating Regulatory Feedback into CMC Actions

As the product progressed toward Phase 2, regulatory feedback required greater definition of the CMC package. Particular attention was required for the regulatory designation and control of the botanical starting material and drug substance, contaminant controls, analytical considerations and the structure of the Module 3 documentation.

The response involved translating regulatory questions into practical actions distributed across the Sponsor, contract manufacturing organisations, suppliers and external laboratories.

This included clarifying the relationship between the botanical starting material, the resulting GMP drug substance and the finished drug product. Manufacturing and testing information was aligned with the relevant CTD Module 3 sections, while phase-appropriate justifications were developed where available development data were not yet sufficient to establish definitive commercial-stage acceptance criteria.

This distinction was important. A Phase 2 development program must provide appropriate assurance over material and product quality, but the available evidence may continue to develop. Controls therefore needed to reflect the state of scientific and process knowledge rather than assume that every attribute had already reached its final commercial definition.

Controlling the Botanical Starting Material and Drug Substance

The botanical origin of the product created a significant control consideration because naturally derived materials can exhibit variability that must be understood and managed within the pharmaceutical manufacturing process.

A control strategy was developed for introduction of the botanical starting material into the pharmaceutical supply chain. This incorporated specifications, supplier controls, incoming testing and traceability requirements.

The relationship between the starting material and the resulting GMP drug substance was also defined through manufacturing and control narratives. This provided a structured basis for connecting upstream material characteristics with downstream pharmaceutical quality attributes.

Phase 2 drug substance specifications addressed attributes including identity, active content, physical characteristics, moisture and microbiological quality, together with other relevant characteristics. The strategy differentiated between attributes for which defined acceptance criteria were appropriate and characteristics that required continued monitoring as development knowledge accumulated.

This approach allowed naturally variable material characteristics to be addressed without assuming that every source of variability could be eliminated at an early stage of development.

Developing the Drug Product Manufacturing Control Strategy

The finished drug product required a corresponding control strategy covering manufacturing and packaging operations. Manufacturing protocols, batch documentation, critical in-process controls and process parameters were reviewed alongside sampling frequencies and escalation criteria for adverse trends or manufacturing interruptions.

Phase 2 specifications, analytical methods and acceptance criteria were developed and reviewed for the drug product. Dosage-unit uniformity and sampling strategies were also assessed against applicable pharmacopoeial requirements.

Visual inspection and risk-based sampling approaches were developed to address potential drug product and packaging defects. Where multiple clinical presentations were involved, bracketing assessments were considered to determine how the available evidence could appropriately represent the relevant presentations.

The objective was to establish sufficient control over clinical batches while retaining a risk-based approach appropriate to the scale and maturity of the development program.

Analytical Development and Stability

Analytical development formed another major component of the Phase 2 strategy. The program required a coherent approach to compendial, non-compendial and biological methods used for control of both drug substance and drug product.

A phase-appropriate analytical validation strategy was developed to define the level of method validation required for the clinical development stage. Forced-degradation strategies were also developed to challenge analytical methods and assess their ability to detect meaningful changes in the drug substance and formulated product.

Stability studies were addressed through protocols incorporating long-term, intermediate and accelerated conditions, with tests and timepoints selected according to risk and available product knowledge.

Packaging configuration also required consideration. Bracketing justifications were developed where appropriate to reduce unnecessary stability testing while maintaining suitable representation of the clinical presentations.

Together, these activities provided an analytical and stability framework capable of generating data to support Phase 2 development while allowing the control strategy to mature as additional information became available.

Managing Botanical Contamination and Microbiological Risks

The biological origin of the starting material required an end-to-end contaminant-control strategy extending from the botanical starting material through the drug substance to the finished drug product.

Analytical approaches were evaluated according to the characteristics of the relevant material and matrix. Specialist external laboratories were assessed and supported through qualification activities, including consideration of matrix-specific method suitability.

Microbiological specifications and specified-organism testing were reviewed against applicable pharmacopoeial requirements. The strategy also considered the practical limitations associated with small clinical batch sizes, ensuring that testing and assurance activities remained proportionate to the development context.

Additional risk assessments addressed elemental impurities, residual solvents and nitrosamines. Supplier knowledge, manufacturing-process information and available analytical data were used to determine where direct testing was warranted and where a documented risk assessment could provide an appropriate basis for control.

Managing a Multi-Vendor GMP Supply Chain

The outsourced operating model created another important quality interface. Starting-material supply, manufacturing and specialist analytical testing were distributed across multiple external organisations, making clearly defined responsibilities and traceability essential.

CMOs, analytical laboratories and specialist providers were qualified and risk-categorised using a phase-appropriate vendor-management approach. Vendor questionnaires, GMP licences, ISO/IEC 17025 accreditation and product-specific analytical method suitability were reviewed as part of the assessment process.

Quality Agreements and responsibility allocations were developed across the Sponsor, CMO, starting-material supplier and outsourced service providers. These arrangements established clearer expectations for activities performed outside the Sponsor's direct organisational structure.

Technical and Quality questions were also addressed directly with CMOs, suppliers and laboratories. Quality support extended into practical aspects of clinical supply, including input into clinical labelling, shipment and temperature-monitoring arrangements.

This model helped connect individual supplier activities into a broader pharmaceutical quality framework rather than treating each external organisation as an isolated component.

Batch Release, Investigations and Quality Risk Management

Clinical batch manufacture and release required ongoing Sponsor oversight. One area of consideration was the relationship between manufacturing timelines and completion of analytical testing, requiring risks to be assessed without compromising the quality decision-making process.

Formal Quality Risk Management principles were applied to manufacturing, analytical and supply-chain issues. The intent was to evaluate risks according to their potential impact and available evidence rather than automatically applying controls designed for a mature commercial operation.

Where atypical manufacturing observations occurred, structured investigation approaches were supported. These included Is/Is Not analysis and fishbone or root-cause frameworks to organise the investigation and identify potential contributing factors.

Importantly, the control strategy was treated as an evolving system. As product, process and analytical knowledge accumulated, Quality, CMC and regulatory activities were reviewed and adjusted accordingly.

Building a Control Strategy That Could Mature with the Program

The engagement ultimately expanded beyond its initial PQS and DMS scope into continuing Quality, CMC and regulatory support throughout Phase 2 development.

The resulting framework provided GMP governance appropriate for a clinical-stage organisation without unnecessarily building a commercial-stage quality infrastructure before the supporting development data were available.

The integrated CMC strategy connected botanical starting-material controls with drug substance and drug product manufacturing, analytical methods, stability studies, supplier oversight and regulatory documentation. This integration was particularly important because changes or findings in one area could affect requirements elsewhere in the development program.

Regulatory feedback was incorporated into the evolving CMC package, strengthening the definition of material controls and clarifying manufacturing and testing responsibilities. Phase-appropriate specifications, analytical strategies and other controls were established to provide assurance for clinical development while remaining capable of refinement as additional data were generated.

The outsourced manufacturing and analytical network also received greater definition through risk-based vendor qualification, Quality Agreements and documented responsibility allocations.

Outcome

The engagement demonstrates how a botanical-derived pharmaceutical product can be supported through the transition from research and development into Phase 2 clinical development using a control strategy that evolves with scientific and process knowledge.

The initial requirement for a phase-appropriate PQS and DMS developed into a broader program encompassing Quality, CMC, analytical development, stability, manufacturing oversight, vendor management and regulatory documentation.

For a botanical-derived product, effective development required more than establishing controls around the finished dosage form. The strategy extended upstream into the botanical starting material and downstream across manufacturing, analytical testing, stability and clinical supply.

The resulting framework provided a structured basis for GMP governance, material control, analytical assurance and outsourced supply-chain oversight while recognising the information available at the Phase 2 stage. Rather than treating development controls as fixed commercial requirements, the program established mechanisms through which specifications, analytical approaches, manufacturing controls and quality oversight could continue to mature as evidence accumulated.

This progression illustrates the importance of maintaining alignment between pharmaceutical quality systems and CMC development. For a clinical-stage sponsor managing a complex botanical-derived product and multi-vendor supply chain, the quality system, technical control strategy and regulatory package must develop together if the program is to maintain traceability, appropriate oversight and scientifically justified controls throughout clinical development.